Clinical Trials Logo

Diabetes Mellitus clinical trials

View clinical trials related to Diabetes Mellitus.

Filter by:

NCT ID: NCT03805412 Recruiting - Obesity Clinical Trials

Continuous Glucose Monitoring in Diabetes and Prediabetes

Start date: January 2019
Phase: N/A
Study type: Interventional

Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.

NCT ID: NCT03805191 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients

FLAT
Start date: January 10, 2019
Phase:
Study type: Observational

This is a multicentre observational study to investigate the improvement in glucose fluctuation of sufficient acarbose therapy on type 2 diabetes patient with high blood glucose fluctuation

NCT ID: NCT03804983 Recruiting - Clinical trials for Type 1 Diabetes Mellitus

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

Start date: January 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.

NCT ID: NCT03804905 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

STUDIIO-Diabetes Pilot: STUdy of Drug Insurance to Improve Outcomes of Diabetes

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Canada is the only country with a universal health insurance system that does not provide coverage for prescription drugs to all residents. One-third of working-age Canadians have no insurance. Importantly, many of these uninsured patients already face other barriers to good health: low income, new immigrants, single mothers, etc. For these patients, taking prescription drugs - especially chronic disease treatments that may be required lifelong - can be difficult due to high costs. Patients skip doses, delay renewing prescriptions, or simply do not fill prescriptions recommended by their doctors, because they do not have insurance to cover the costs of prescriptions. Previous research by our team has suggested that the lack of a universal drug insurance program for working-age Canadians affects the health and well-being of low-income people with diabetes. The goal of our research is to determine the clinical and economic impact of providing drug coverage for uninsured type 2 diabetics.

NCT ID: NCT03804411 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Prognostic Predictors of Response to Hypoglycemic Therapy

Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.

NCT ID: NCT03803072 Not yet recruiting - Clinical trials for Diabetes, Gestational

A Novel Diet Approach to Combat Gestational Diabetes

Start date: January 2019
Phase: N/A
Study type: Interventional

There is an urgent need to implement novel diet approaches to combat the increasing rates of gestational diabetes mellitus (GDM). The primary aim of this study is to establish the feasibility of time-restricted eating in pregnancy, to prepare for future larger controlled trials in this research project to determine the efficacy of time-restricted eating in women at risk of GDM. Expectations: 1. Women who have an increased risk of GDM will be able to adhere to time reduced eating during pregnancy. 2. Time reduced eating will improve short-term glycemic control in pregnancy.

NCT ID: NCT03802942 Not yet recruiting - Hypoglycemia Clinical Trials

Prevention of Hypoglycemia Among Diabetes Patients Admitted to Internal Medicine Departments With Nutritional Care

MENU-DM
Start date: March 2019
Phase: Phase 4
Study type: Interventional

This is a prospective randomized study to evaluate the efficacy of nutritional intervention for the prevention of hypoglycemia among diabetes patients with low albumin level that are admitted to internal medicine units, regardless of the reason for admission. All patients suitable for participation in the study will be asked to participate and be randomized to the interventional arm or the control arm. After admission to the internal medicine unit, eligible patients will be asked to participate in the study. After signing an informed consent form, patients will be randomized to the treatment or control arms. For patients allocated to the treatment arm, the physician in charge will prescribe 2 portions of GlucernaTM per day as part of the treatment protocol. The nurse in charge of the patient (at either the morning or evening shifts) will make sure the patient is receiving and consuming the ONS. For every patient included in the interventional arm, 2 bottles of GlucernaTM will be supplied to the patient, one at 08:00 with the morning medications, and one at 16:00 with the evening medications. For clarification purposes, the GlucernaTM will be supplied on top of the designated meal plan, as "over-feeding". Evaluation of adequate ONS consumption will be performed 2-3 hours after the dispensing of the ONS (at 10:00-11:00 and 19:00-21:00), and the amount consumed will be documented. Patients in the control arm will receive no oral nutritional supplementation, and their caloric intake will be composed of the food supplied by the hospital. Other analysis will be considered usual care. Additional diet consultations as requested by the medical staff will constitute usual care, and the patient will continue the study. The duration of ONS treatment will be the entire length of hospital stay. Upon discharge, a recommendation to continue nutritional care will be added to the patients' discharge letters but no oral nutritional supplement (ONS) will be prescribed or dispensed. Following discharge, a 30-day follow-up call will be made to ascertain whether the patient is alive, whether the patient was re-admitted or re-hospitalized, and the usage of ONS prescribed by the family/general practitioner that was consumed after the hospital discharge.

NCT ID: NCT03802825 Not yet recruiting - Diabetes Clinical Trials

Addressing Social Determinants of Health & Diabetes Self-Management in Vulnerable Populations

Start date: February 4, 2019
Phase: N/A
Study type: Interventional

In this pilot and feasibility study, the investigator will randomize 100 African-American, Hispanic, and/or Medicaid (all race/ethnicities) patients from KPNW with A1C ≥ 8 to one of two 6-month interventions: 1) patient navigation only; or 2) patient navigation + diabetes self-management training. Feasibility of a large-scale, pragmatic, randomized trial will be determined and preliminary effectiveness of treatment arms on A1C reduction among racial/ethnic minority and low-income patients with poorly managed diabetes will be examined.

NCT ID: NCT03802487 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal administration Secondary Objectives: - To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide (M19) after a single oral dose of sotagliflozin and an IV microdose of a 14C-sotagliflozin tracer without charcoal administration - To assess the safety and tolerability of single doses of sotagliflozin when administered with and without charcoal

NCT ID: NCT03801824 Completed - Clinical trials for Gestational Diabetes Mellitus

Effect of Low Glycemic Index on Gestational Diabetes Mellitus

MyLGI
Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether glycemic index is effective in the treatment of maternal glycemia and pregnancy outcomes in women with Gestational Diabetes Mellitus.